ストックスクリーナーアプリを入手
2.90
3.94%
0.11
Prime Medicine Inc (PRME) 最新ニュース
Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans? - Simply Wall St
Prime Medicine's SWOT analysis: gene editing firm's stock faces pivotal 2025 - Investing.com
When Would Be The Best Time To Buy Prime Medicine Inc (NASDAQ: PRME) Stock? - Stocks Register
Prime Medicine, Inc. (NYSE:PRME) Receives $12.67 Consensus Price Target from Analysts - Defense World
Prime Medicine Files for Resale of 11 Million Shares - Marketscreener.com
Layoff Tracker: Bavarian, BenevolentAI, Chroma Medicine and Nvelop Therapeutics Cut Staff - BioSpace
Prime Medicine initiated with an Outperform at JMP Securities - MSN
Prime Medicine (NYSE:PRME) Stock Rating Upgraded by Citizens Jmp - MarketBeat
Prime Medicine, Inc. (NYSE:PRME) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Fmr LLC Sells 184,541 Shares of Prime Medicine, Inc. (NYSE:PRME) - MarketBeat
Prime Medicine's SWOT analysis: gene editing firm's stock faces pivotal year - Investing.com Canada
Prime Medicine stock a top pick for gene editing, says JMP Securities - Investing.com Canada
Prime Medicine (NYSE:PRME) Now Covered by Analysts at JMP Securities - MarketBeat
Intech Investment Management LLC Acquires Shares of 14,102 Prime Medicine, Inc. (NYSE:PRME) - Defense World
Prime Medicine (NYSE:PRME) Earns Buy Rating from Guggenheim - Defense World
Vestal Point Capital LP Purchases 620,000 Shares of Prime Medicine, Inc. (NYSE:PRME) - MarketBeat
Comparing Century Therapeutics (NASDAQ:IPSC) & Prime Medicine (NYSE:PRME) - Defense World
Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies - Seeking Alpha
Oppenheimer & Co. Inc. Has $69,000 Stock Holdings in Prime Medicine, Inc. (NYSE:PRME) - Defense World
GSA Capital Partners LLP Invests $383,000 in Prime Medicine, Inc. (NYSE:PRME) - Defense World
Brokerages Set Prime Medicine, Inc. (NYSE:PRME) Target Price at $13.25 - Defense World
Chardan Capital Raises Earnings Estimates for Prime Medicine - MarketBeat
FY2024 EPS Forecast for Prime Medicine Increased by Analyst - Defense World
FY2024 EPS Estimates for Prime Medicine Reduced by Analyst - Defense World
Wedbush Forecasts Prime Medicine FY2024 Earnings - Defense World
Prime Medicine, Inc. (NYSE:PRME) Receives $13.25 Consensus Target Price from Analysts - MarketBeat
Prime Medicine (NYSE:PRME) Raised to Sell at StockNews.com - Defense World
FY2024 EPS Estimate for Prime Medicine Decreased by Analyst - MarketBeat
Brokers Issue Forecasts for Prime Medicine FY2024 Earnings - MarketBeat
Chardan Capital Issues Pessimistic Forecast for Prime Medicine (NYSE:PRME) Stock Price - Defense World
Prime Medicine (NYSE:PRME) Earns “Buy” Rating from HC Wainwright - Defense World
Prime Medicine Reports Q3 2024 Financial Progress - TipRanks
Prime Medicine (NYSE:PRME) Given "Buy" Rating at HC Wainwright - MarketBeat
FMR LLC Bolsters Stake in Prime Medicine Inc - GuruFocus.com
Prime Medicine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire
ARK Investment Management LLC Lowers Stock Position in Prime Medicine, Inc. (NYSE:PRME) - MarketBeat
Prime Medicine to Participate in Upcoming Investor Conferences - The Manila Times
Head to Head Review: Prime Medicine (NYSE:PRME) and Invivyd (NASDAQ:IVVD) - Defense World
Prime Medicine (NYSE:PRME) Receives Buy Rating from HC Wainwright - MarketBeat
Prime Medicine Spat with Tessera Rumbles on at ESGCT - Genetic Engineering & Biotechnology News
Prime Medicine receives Investment Bank Analyst Rating Update By Investing.com - Investing.com
Brokerages Set Prime Medicine, Inc. (NYSE:PRME) Price Target at $13.50 - Defense World
Prime Medicine Presents In Vivo Proof-of-Concept Data - GlobeNewswire
Prime Medicine Advances Gene Editing for Liver Diseases - TipRanks
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):